

Nanalyze
Nanalyze is a media and research firm founded by finance professionals with decades of experience. We share insights about disruptive technology stocks in a language that is future-proof and easy to understand. Read all the Nanalyze Premium articles you'd like for free! Sign up for a 30-day trial of our monthly subscription with no strings attached: https://www.nanalyze.com/become-a-nanalyze-premium-subscriber/
Episodes


Explosive AI Growth Pays Huge Dividends

The Biggest Risk TSM Stock Bulls Don't See

This Won't End Well.

How to Find Great Dividend Stocks to Buy (Step by Step)

DXYZ: Major Crash Incoming [WARNING]

What Rubrik's IPO Means for Investors

NVIDIA's Plan to Change the World

Big Problems with Soundhound Stock

40 AI ETFs_How to find the best ones

ARK Predicts Trillions in Profits

Is This AI Drug Discovery Stock a Bargain?
AbCellera’s recent 23% share price decline highlights significant concerns regarding the viability of its AI-powered drug discovery engine. While the company maintains $780 million in cash, its business model faces scrutiny due to a 41% failure rate on completed programs and a lack of meaningful late-stage pipeline pro...

Should You Invest in RDDT?

Why We Never Use Stop Losses

Why Tesla is a Buy at $127 a Share

The Opportunity of a Lifetime

Why we held this stock to bankruptcy

MicroStrategy's CEO is Disconnected from Reality

An AI Drug Discovery Stock We Like

This Time It's Different
Follow this podcast in Podwise
Sign in to get AI summaries, transcripts and mind maps for any episode, including new ones.
